Zambelli, A., Cazzaniga, M., La Verde, N., Munzone, E., Antonazzo, I., Mantovani, L., et al. (2023). A cost-consequence analysis of pertuzumab in the neoadjuvant treatment of high-risk HER2+Early-Stage Breast Cancer (EBC): health-economic considerations for drug availability in Italy. CANCER RESEARCH, 83(5) [10.1158/1538-7445.SABCS22-P6-08-01].
A cost-consequence analysis of pertuzumab in the neoadjuvant treatment of high-risk HER2+Early-Stage Breast Cancer (EBC): health-economic considerations for drug availability in Italy
Mantovani, LG;Cortesi, PA
2023
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
